Fresh Funding Pushes Inflazome Into Clinic With Inflammation Inhibitors
Executive Summary
With $46m funding fresh in its pocket, Dublin biotech Inflazome tells Scrip how it will advance its clinical candidates in multiple indications.
You may also be interested in...
GSK-Backed Sitryx Launches With Six Immunometabolism Eggs In Its Basket
GlaxoSmithKline, SV Health Investors and Sofinnova are among the backers of a new Oxford-based biotech which has raised $30m in series A financing and boasts a strong line-up of academic founders. CEO Neil Weir outlines Sitryx's raison d'etre.
Forbion Attracts New Investors Closing IV Fund At €360M
European life science companies can expect to get access to almost €290m from Forbion as the EU-based venture capitalist closes its fourth fund at an oversubscribed €360m.
Inflammasome's Time Has Come, Says Ex-GSK NodThera Chief After £28m Financing
CSO and acting CEO of UK-Based biotech outlines to Scrip plans to develop next generation NLRP3 inflammasome inhibitors to treat diseases driven by chronic inflammation.